Kalaris Therapeutics says TH103 Phase 1b/2 trial in neovascular AMD is enrolling patients

Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc.

KLRS

0.00
  • Kalaris Therapeutics set a July 17, 2026 ASRS presentation for Phase 1a first-in-human data on TH103 in treatment-naïve wet AMD.
  • Results have not yet been presented; the update is positioned as an early read on safety and initial clinical activity.
  • A Phase 1b/2 multiple-ascending-dose trial in neovascular AMD is actively enrolling and dosing, supporting dose selection for a potential Phase 3 program.
  • Initial Phase 1b/2 data are expected in 1H 2027, a key catalyst for TH103’s development timeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230800PRIMZONEFULLFEED9750704) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.